David Alan Anthoney

454 total citations
9 papers, 186 citations indexed

About

David Alan Anthoney is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, David Alan Anthoney has authored 9 papers receiving a total of 186 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in David Alan Anthoney's work include Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers), Cancer Genomics and Diagnostics (2 papers) and Genetic factors in colorectal cancer (2 papers). David Alan Anthoney is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers), Cancer Genomics and Diagnostics (2 papers) and Genetic factors in colorectal cancer (2 papers). David Alan Anthoney collaborates with scholars based in United Kingdom, United States and France. David Alan Anthoney's co-authors include Darius F. Mirza, Pippa Corrie, John Bridgewater, Harpreet Wasan, David Cunningham, John Primrose, Juan W. Valle, T.R. Jeffry Evans, O. James Garden and Jonathan Wadsley and has published in prestigious journals such as Journal of Clinical Oncology.

In The Last Decade

David Alan Anthoney

9 papers receiving 183 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Alan Anthoney United Kingdom 6 136 126 110 20 17 9 186
Najib Lamfichekh France 7 110 0.8× 120 1.0× 56 0.5× 13 0.7× 11 0.6× 7 171
Jo Dent United Kingdom 5 49 0.4× 149 1.2× 76 0.7× 20 1.0× 15 0.9× 9 177
Thatthan Suksombooncharoen Thailand 3 154 1.1× 135 1.1× 62 0.6× 30 1.5× 16 0.9× 5 171
Kabuto Takano Japan 8 131 1.0× 103 0.8× 115 1.0× 9 0.5× 23 1.4× 29 189
Ichiro Iwanaga Japan 5 51 0.4× 128 1.0× 143 1.3× 18 0.9× 13 0.8× 17 204
Y.S. Park South Korea 4 81 0.6× 113 0.9× 70 0.6× 30 1.5× 19 1.1× 12 147
Vallerie Gordon Canada 6 41 0.3× 124 1.0× 55 0.5× 9 0.5× 38 2.2× 13 162
Tarek Boussaha France 5 114 0.8× 85 0.7× 74 0.7× 18 0.9× 6 0.4× 9 140
Hajime Ushigome Japan 10 106 0.8× 113 0.9× 94 0.9× 12 0.6× 35 2.1× 30 225
Juan Cundom Argentina 3 150 1.1× 148 1.2× 63 0.6× 36 1.8× 13 0.8× 6 181

Countries citing papers authored by David Alan Anthoney

Since Specialization
Citations

This map shows the geographic impact of David Alan Anthoney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Alan Anthoney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Alan Anthoney more than expected).

Fields of papers citing papers by David Alan Anthoney

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Alan Anthoney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Alan Anthoney. The network helps show where David Alan Anthoney may publish in the future.

Co-authorship network of co-authors of David Alan Anthoney

This figure shows the co-authorship network connecting the top 25 collaborators of David Alan Anthoney. A scholar is included among the top collaborators of David Alan Anthoney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Alan Anthoney. David Alan Anthoney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Primrose, John, Richard Fox, Daniel H. Palmer, et al.. (2017). Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.. Journal of Clinical Oncology. 35(15_suppl). 4006–4006. 134 indexed citations
2.
Jones, Robert H., David Alan Anthoney, Robert J. Jones, et al.. (2016). FIESTA: A phase Ib and pharmacokinetic trial of AZD4547 in combination with gemcitabine and cisplatin.. Journal of Clinical Oncology. 34(15_suppl). 4521–4521. 2 indexed citations
3.
Evans, T.R. Jeffry, Thomas Aparicio, Karine Le Malicot, et al.. (2016). GLOBAL BALLAD: An International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002).. Journal of Clinical Oncology. 34(15_suppl). TPS4154–TPS4154. 7 indexed citations
4.
Schöffski, Patrick, Agnieszka Woźniak, Silvia Stacchiotti, et al.. (2015). Activity of crizotinib (C) in patients (pts) with clear cell sarcoma (CCSA) in EORTC phase II trial 90101 "CREATE".. Journal of Clinical Oncology. 33(15_suppl). 10542–10542. 6 indexed citations
5.
Cook, Natalie, Bristi Basu, Donna-Michelle Smith, et al.. (2014). A phase I trial of the ɣ-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 32(15_suppl). 4116–4116. 9 indexed citations
6.
Valle, Juan W., Harpreet Wasan, Mark Jitlal, et al.. (2014). ABC-03: A randomized phase II trial of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract cancer (ABC).. Journal of Clinical Oncology. 32(15_suppl). 4002–4002. 4 indexed citations
7.
Salazar, Ramón, Jean Philippe Metges, David Alan Anthoney, et al.. (2013). IMAGE, a randomized phase Ib/II study of elisidepsin (E) as a single agent in pretreated advanced gastroesophageal (GE) cancer.. Journal of Clinical Oncology. 31(4_suppl). 92–92. 2 indexed citations
8.
Plummer, Ruth, T.R. Jeffry Evans, David Alan Anthoney, et al.. (2012). A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer.. Journal of Clinical Oncology. 30(15_suppl). 2552–2552. 6 indexed citations
9.
Hennig, I., Jay Naik, Sarah Brown, et al.. (2008). Severe Sequence-Specific Toxicity When Capecitabine Is Given After Fluorouracil and Leucovorin. Journal of Clinical Oncology. 26(20). 3411–3417. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Najib Lamfichekh Breakdown of academic impact, for papers by Jo Dent Breakdown of academic impact, for papers by Thatthan Suksombooncharoen Breakdown of academic impact, for papers by Kabuto Takano Breakdown of academic impact, for papers by Ichiro Iwanaga Breakdown of academic impact, for papers by Y.S. Park Breakdown of academic impact, for papers by Vallerie Gordon Breakdown of academic impact, for papers by Tarek Boussaha Breakdown of academic impact, for papers by Hajime Ushigome Breakdown of academic impact, for papers by Juan Cundom
Rankless by CCL
2026